Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade

Los Angeles, USA, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade 

The Non-Small Cell Lung Cancer Pipeline appears rich with several novel therapeutic agents in different stages of clinical development. The NSCLC pipeline therapies include a slew of Small molecules, gene therapies, CAR-T Therapies, Immunotherapies, and Serum globulins that are expected to transform the NSCLC market landscape dramatically. 

DelveInsight’s Non-Small Cell Lung Cancer (NSCLC) Pipeline Report 2020 report offers comprehensive insights into the present treatment landscape. 

Non-Small Cell Lung Cancer Pipeline Report Highlights

• More than 200 pharma and biotech companies are developing therapies for NSCLC. 
• Pharma players, including Spectrum Pharmaceuticals, Bristol-Myers Squibb, Merck, Eisai, Novartis Pharmaceuticals, Ariad Pharmaceuticals, Takeda, Regeneron Pharmaceuticals, Innovent Biologics, among others, have their Non-Small Cell Lung Cancer drug candidates in the mid to advanced stage, i.e., phase III and Phase II. 
• Several companies are primarily focusing on therapies targeting the first-line setting. 
• Among all the available therapies in the NSCLC market, Keytruda (pembrolizumab) is expected to emerge as one of the most promising therapies in the study period 2017-30 after Opdivo (nivolumab). 
• In NSCLC cases with EGFR T790M resistance mutations, Tagrisso is expected to dominate the market.
• JNJ-6372 and TAK-788 are mainly targeting EGFR exon 20 insertion mutations are also expected to generate good revenue in the coming years.
• The companies and academics are working to assess challenges and seek opportunities that could influence Non-Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Non-Small Cell Lung Cancer.

Have a query? Ask our Experts @ Non-Small Cell Lung Cancer Pipeline Sample Page

The report provides a detailed analysis of pipeline therapies segmented by different phases of development, major pharmaceutical companies developing the drug, route of administration, molecule type, and product type. 

Know more about the NSCLC pipeline report offerings: Non-Small Cell Lung Cancer Pipeline Report

Mirati Therapeutics recently announced preliminary results of a trial investigating its selective and potent potential first-in-class KRAS G12D inhibitor, MRTX1133 (adagrasib) demonstrating well-tolerance, efficacy, and durable anti-tumor activity; 45% confirmed ORR and 96% DCR across Phase 1/1b and Phase 2 monotherapy cohorts in patients with advanced NSCLC. Advaxis also announced updated clinical trial results from the combination arm of the ongoing Phase 1/2 study testing ADXS-503 combined with Keytruda. The results demonstrated an approximate 50% improvement in disease control rate versus the rates reported in other checkpoint rechallenge studies. Similarly, Amgen announced positive Phase 2 results from CodeBreaK 100 clinical study, investigating Sotorasib (AMG 510) patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC) demonstrating promising objective response rate and efficacy. 
While BMS and Merck announced positive results in different trials for their leading candidates in NSCLC, Opdivo, and Keytruda respectively, Tagrisso (AstraZeneca) received the US FDA granted Priority Review for the adjuvant treatment of patients with early-stage (IB, II, and IIIA) epidermal growth factor receptor-mutated (EGFRm) NSCLC after complete tumor resection with curative intent.

The present NSCLC therapeutics market heavily relies on targeted therapies and immunotherapies, focusing on cancer-specific to certain mutations. At present, Keytruda, Opdivo, Tecentriq, Tagrisso are present in the market as expensive branded therapies. Some of the therapies fail to prove their clinical effectiveness relative to their cost. Thus, cost-effectiveness poses to be a major challenge in the market, which the upcoming therapies are expected to face. 

However, the pipeline therapies are expected to add revenue dramatically and will prove to be an impact rendering driver in the NSCLC market size growth. Incremental healthcare expenditure as well as in R&D in the domain will further help pharma companies to seek opportunities in the market. 

For further product details, contact @ Non-Small Cell Lung Cancer Pipeline 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Non-Small Cell Lung Cancer drugs?
• How many Non-Small Cell Lung Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage and late-stage development for the treatment of Non-Small Cell Lung Cancer?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Non-Small Cell Lung Cancer therapeutics?
• What are the recent trends, drug types, and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Non-Small Cell Lung Cancer and their status?
• What are the key designations that have been granted to emerging drugs?

Scope of the report

• Coverage: Global 
• Phases: 
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) 
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

• Therapeutic assessment of the pipeline drugs by the Route of Administration:
  • Subcutaneous
  • Intramuscular
  • Intratumoral
  • Intravenous
  • Molecule Type

• Comprehensive coverage of key companies and their detailed insights into their drug candidates. 
• Major collaborations between pharmaceutical companies and academia. 
• Ongoing clinical trials segmented into different phases. 
• Recent happenings on the research front and news front in the NSCLC market. 

Non-Small Cell Lung Cancer Therapeutics

• Nazartinib/EGF816: Novartis Pharmaceuticals
• Capmatinib/INC280: Novartis Pharmaceuticals
• Telisotuzumab Vedotin: AbbVie
• JNJ-61186372/JNJ-6372: Janssen Pharmaceuticals
• Ensartinib/X-396: Xcovery
• Selpercatinib (LY3527723/LOXO-292): Eli Lilly and Company
• SAR408701: Sanofi
• Braftovi/encorafinib + Mektovi/binimetinib: Pfizer
• PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/Seattle Genetics
• TAK-788: Takeda Pharmaceuticals
• Canakinumab/(ACZ885): Novartis
• BAVENCIO (Avelumab): Merck/Pfizer
• Veliparib: AbbVie
• Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers Squibb/Beigene
• M7824: Merck/GlaxoSmithKline
• AMG 510: Amgen
• INCMGA00012 (MGA012): Incyte Corporation
• Romiplostim: Amgen
• TEPMETKO (tepotinib): Merck

Table of Contents 

Related Reports 

Non-Small Cell Lung Cancer- Market Forecast
DelveInsight’s ‘Non-Small Cell Lung Cancer (NSCLC) - Market Insights, Epidemiology, and Market Forecast - 2030’ report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the 7MM (the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan).

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.